Key result
Direct-acting small molecules targeting the enterovirus capsid have largely failed in clinical trials due to insufficient efficacy, off-target effects, and a low barrier to resistance.
This review highlights the therapeutic potential and challenges of developing small molecule and peptide-based antivirals targeting the entry mechanisms of enteroviruses.
EV capsid binders need in vivo validation before any clinical consideration; leaves open targeted therapies for enteroviral myocarditis.
Viruses from the genus Enterovirus (EV) of the Picornaviridae family are known to cause diseases such as hand foot and mouth disease (HFMD), respiratory diseases, encephalitis and myocarditis. The capsid of EV is an attractive target for the development of direct-acting small molecules that can interfere with viral entry. Some of the capsid binders have been evaluated in clinical trials but the majority have failed due to insufficient efficacy or unacceptable off-target effects. Furthermore, most of the capsid binders exhibited a low barrier to resistance. Alternatively, host-targeting inhibitors such as peptides derived from the capsid of EV that can recognize cellular receptors have been identified. However, the majority of these peptides displayed low anti-EV potency (µM range) as compared to the potency of small molecule compounds (nM range). Nonetheless, the development of anti-EV peptides is warranted as they may complement the small-molecules in a drug combination strategy to treat EVs. Lastly, structure-based approach to design antiviral peptides should be utilized to unearth potent anti-EV peptides.
No takes yet. Share an insight, caveat, or question.
Anasir et al. (2021) conducted a review in Enterovirus infections. Antivirals blocking entry of enteroviruses was evaluated. Direct-acting small molecules targeting the enterovirus capsid have largely failed in clinical trials due to insufficient efficacy, off-target effects, and a low barrier to resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: